Supervisory Board

Biography

Dieter K. Weinand, M.S. (born in 1962, American citizen) was appointed Member of the Supervisory Board on June 11, 2026.

Mr. Weinand brings more than 30 years of global leadership experience in the pharmaceutical industry, encompassing senior executive, commercial, operational and strategic roles across major international healthcare companies. He previously served as a member of the Board of Management of Bayer AG and as President, Chief Executive Officer and Chairman of the Board of Bayer Pharmaceuticals AG, where he led an integrated global pharmaceutical business.

Earlier in his career, Mr. Weinand held senior leadership positions at Sanofi, Pfizer and Bristol Myers Squibb, with responsibilities spanning global and regional business leadership, commercial strategy and organizational transformation. Across these roles, he gained extensive experience in the development, launch and commercialization of pharmaceutical products across a broad range of therapeutic areas and in building and managing international partnerships.

Mr. Weinand has substantial experience in corporate governance and currently serves on the boards of public and private biotechnology companies, including Replimune and Coya Therapeutics. He has also previously held board and leadership roles in international pharmaceutical industry associations, including PhRMA, EFPIA and IFPMA.

Mr. Weinand holds a Master of Science degree in Pharmacology and Toxicology from Long Island University, New York, and a Bachelor’s degree in Biology from Concordia College, New York.

Biography 

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2027.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as Chairman of the board of BIO Deutschland e.V. Mr Roland Sackers (CFO of QIAGEN N.V.) is independent. QIAGEN N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

Biography 

Mrs Camilla Macapili Languille (born 1983, Canadian citizen) was appointed Member of the Supervisory Board on 22 June 2022. Her current term will expire at the end of the Annual General Meeting held in the year 2027.

Camilla Macapili Languille is Deputy CEO of Mubadala’s Direct Investments platform, which executes global direct investments with a focus on private equity and actively manages a portfolio targeting growth-oriented companies across a range of sectors, including Healthcare, Consumer, Financial Services, Industrial & Business Services, Energy & Sustainability, and Globalfoundries (semiconductors).

Camilla has been with Mubadala Direct Investments since 2013 and has led the buildout of its global Healthcare portfolio and investments team. As the former Head of Healthcare, Camilla was responsible for executing investments in companies such as PCI Pharma, Envirotainer, Evotec, and Norstella, amongst others, and for building a ~25-person global investments team across Abu Dhabi, New York, London, and Beijing. Prior to launching the Healthcare business, Camilla was responsible for managing the Semiconductors portfolio, including Globalfoundries and Advanced Micro Devices (AMD). She started her journey in Mubadala overseeing the Utilities and Mining portfolios.

Prior to joining Mubadala, Camilla previously worked in M&A for Daiwa Capital and Société Générale based in Paris, as well as in private equity and growth equity investments for Virgin Group in London, where she managed the Special Situations portfolio and supported the launch of Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London.

Camilla currently serves on the Boards of Globalfoundries Inc and PCI Pharma. She also serves as the Co-Chair of Mubadala’s Direct Investments Investment Committee and as a member of Mubadala’s Group Investment Committee.

Camilla holds a Bachelor’s degree in Economics & Political Science from Columbia University (summa cum laude). She is a Canadian by nationality, has lived in 14 countries, and is fluent in English and French.

Biography

Dr Ulmer-Eilfort (born in 1962, German citizen) has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. As a Partner with PSP München, she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions.

Previously, Dr Ulmer-Eilfort was a Partner with the international law firm Baker McKenzie where she was also a member of the Global Executive, chairing the Global Financial Committee and overseeing the budgeting process and budget controls worldwide.

Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is member of the advisory board of Proxygen GmbH. Furthermore, Dr Ulmer-Eilforth serves as member of the Supervisory Board of Affimed NV. 

Biography

Dr Duncan McHale (born 1966, British citizen) is Co-Founder and Senior Development Clinician at Weatherden Ltd, based in London, UK, a position he has held since 2017, as well as Chair of the Sydney-based biotech company SynaptraBIO Ltd. Prior to this, Duncan served as the Chief Medical Officer at Evelo Biosciences from 2017 to 2023. From 2011 to 2017, he was the Vice President and Head of Global Exploratory Development at UCB. Between 2008 and 2011, he held various positions at AstraZeneca, culminating in the role of Vice President of Personalized Healthcare and Biomarkers. His career also includes several roles at Pfizer from 1999 to 2007, with his most recent position being Executive Director, European Head of Molecular Profiling and TA lead for Pain, Sex Health, and Urology at Pfizer Global Research and Development's Sandwich Laboratories.

Duncan holds a Doctor of Philosophy (“PhD”) in Human/Medical Genetics from the University of Leeds, and earned his Bachelor of Medicine, Bachelor of Surgery from the University of Newcastle-Upon-Tyne. He has been awarded Membership of the Royal College of Physicians (“MRCP”). Additionally, he was awarded Membership of the Faculty of Pharmaceutical Medicine by distinction, which is the qualification for pharmaceutical physicians in the UK. Duncan retains his medical license to practice. 
 

Biography

Wes Wheeler is a 43 year operations executive starting as a project engineer with Exxon Research & Engineering (now ExxonMobil), but for the past 34 years has held many diverse leadership positions in the pharmaceutical industry. He moved from Exxon to GlaxoSmithKline and worked for 13 years in engineering, marketing and spent his final five years as senior Vice President of Global Manufacturing & Supply. During these final years at GSK, Wes was responsible for transforming the global network of manufacturing sites and managed the merger of GlaxoWellcome and SmithKline Beecham manufacturing operations. He then moved to CEO of DSM Pharmaceuticals, a Division of DSM in the Netherlands, where he was hired to navigate the company through an FDA Warning Letter and turn the company around, which he did in 15 months. After leaving DSM, Wes became President of Valeant Pharmaceuticals International (now Bausch Health) and was responsible for the North American business, global marketing, M&A and the research & development division. Following Valeant, Wes became CEO of Patheon (now a ThermoFisher company), a public company traded on the Toronto Stock Exchange. Patheon was a turnaround opportunity which became the No. 2 contract manufacturing in the industry and at the same time endured a hostile take-private ownership change by JLL Partners. Wes then accepted a role as CEO of Marken, a leading privately held clinical trials logistics company. The Marken turnaround was five years in the making, resulting in the sale of the company to UPS in 2016. Marken is now a billion-dollar company and a global leader in the clinical trials services industry. In his final three years at UPS, Wes was named President of UPS Healthcare, the first vertical business unit ever created at UPS which he grew from $6 to $10 billion in revenue. He was the first private industry leader named to ‘Operation Warp Speed’, the US presidential task force which managing the response to the pandemic. During this time, his new UPS division managed the storage and distribution of nearly 2 billion doses of the COVID-19 vaccine to over 100 countries.

Wes holds a Bachelor’s Degree in Mechanical Engineering and a Masters of Business Administration. He was Director and Chairman of Bushu Pharmaceuticals which was sold to KKR in 2022, He is currently Executive Chairman of BioTouch International and a Board Director with Envirotainer, an EQT company.

Biography

Wolfgang F. Hofmann, M.D. (born in 1968, German citizen) was appointed Member of the Supervisory Board of Evotec SE on June 11, 2026. He brings more than 25 years of international leadership experience in the pharmaceutical and life sciences industries, spanning strategy, corporate development, operations and general management.

Dr. Hofmann is Chief Executive Officer of leon‑nanodrugs GmbH, Munich, Germany. In addition, he serves as a Non‑Executive Director at Trailhead Biosystems, USA. Alongside his leadership roles in large international organizations, he has also been active as an entrepreneur, including the founding of a medical technology company, and brings experience from both corporate and entrepreneurial environments.

Prior to this, Dr. Hofmann held various senior leadership positions within the Fresenius Group and Fresenius Medical Care, with responsibilities across corporate strategy, mergers and acquisitions, innovation and commercial business leadership. In these functions, he gained broad experience in the strategic development and transformation of complex organizations  as well as in the commercialization of innovative healthcare products and services, including in entrepreneurial and emerging company settings.

Earlier in his career, Dr. Hofmann held international roles at Novartis across development, commercial and corporate functions. He began his professional career in medical research, including work in gene therapy at Harvard Medical School, and in clinical practice in Germany.

Dr. Hofmann holds a Doctor of Medicine from Heidelberg University and has completed executive education in finance, management and healthcare at leading international institutions.